Our Pipeline

Takeda Oncology is working to discover and develop innovative new therapies that will make a difference in patients' lives.

The molecules in our development pipeline are ordered by their phase in the clinical development process, and within each phase molecules are ordered alphabetically. Phase 1 trials are conducted to determine proper dosing, while Phase 2 and 3 Studies determine the efficacy, side effects and safety of the therapies being researched.

Certain molecules may be under study for more than one disease area. Click on the arrows to learn more about each one.

Print PDF
Program Phase 1 Phase 2 Phase 3
BRENTUXIMAB VEDOTIN1
DescriptionCD30 Antibody Drug Conjugate Disease(s) under investigationHodgkin Lymphoma, Cutaneous T-Cell Lymphoma, Mature T-Cell Lymphoma, Anaplastic Large Cell Lymphoma
Click here to search clinical trials
BRIGATINIB
DescriptionALK Inhibitor Disease(s) under investigationNon-small Cell Lung Cancer
Click here to search clinical trials
IXAZOMIB
DescriptionProteasome Inhibitor Disease(s) under investigationMultiple Myeloma, Amyloidosis
Click here to search clinical trials
LEUPRORELIN ACETATE2
DescriptionLH-RH Agonist Disease(s) under investigationProstate Cancer, Breast Cancer, new formulation
Click here to search clinical trials
PANITUMUMAB3
DescriptionAnti-EGFR Antibody Disease(s) under investigationColorectal Cancer
Click here to search clinical trials
PEVONEDISTAT
DescriptionNedd8-Activating Enzyme Inhibitor Disease(s) under investigationHigh-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Low-Blast Acute Myelogenous Leukemia
Click here to search clinical trials
DescriptionNedd8-Activating Enzyme Inhibitor Disease(s) under investigationSolid Tumors
Click here to search clinical trials
PONATINIB4
DescriptionBCR-ABL Inhibitor Disease(s) under investigationChronic Myeloid Leukemia
Click here to search clinical trials
DescriptionBCR-ABL Inhibitor Disease(s) under investigationPhiladelphia Chromosome Positive Acute Lymphoblastic Leukemia
Click here to search clinical trials
SAPANISERTIB (TAK-228)
DescriptionTORC1/TORC2 Inhibitor Disease(s) under investigationBreast Cancer, Renal Cell Carcinoma, Endometrial Cancer
Click here to search clinical trials
TAK-117
DescriptionPI3K Alpha Inhibitor Disease(s) under investigationRenal Cell Carcinoma
Click here to search clinical trials
TAK-659
DescriptionSYK/FLT-3 Inhibitor Disease(s) under investigationLymphoma, Acute Myelogenous Leukemia
Click here to search clinical trials
DescriptionSYK/FLT-3 Inhibitor Disease(s) under investigationSolid Tumors
Click here to search clinical trials
TAK-931
DescriptionCDC7 Inhibitor Disease(s) under investigationPancreatic Cancer, Colorectal Cancer
Click here to search clinical trials
VEDOLIZUMAB
DescriptionAnti-α4β7 Antibody Disease(s) under investigationGraft versus Host Disease
Click here to search clinical trials
TAK-243
DescriptionUbiquitin-Activating Enzyme Inhibitor Disease(s) under investigationSolid Tumors
Click here to search clinical trials
TAK-522 (XMT-1522)5
DescriptionHER2 Dolaflexin Antibody Drug Conjugate Disease(s) under investigationBreast Cancer
Click here to search clinical trials
TAK-573
DescriptionCD38-targeted IgG4 fused with attenuated IFNα Disease(s) under investigationMultiple Myeloma
Click here to search clinical trials
TAK-580
DescriptionPan-Raf Inhibitor Disease(s) under investigationSolid Tumors
Click here to search clinical trials
TAK-788 (AP32788)
DescriptionEGFR/HER2 Inhibitor Disease(s) under investigationNon-small Cell Lung Cancer
Click here to search clinical trials
CABOZANTINIB2 Development in Preparation
DescriptionMET, VEGF, AXL and RET Inhibitor Disease(s) under investigationRenal Cell Carcinoma
Click here to search clinical trials
NIRAPARIB6 Development in Preparation
DescriptionPARP Inhibitor Disease(s) under investigationSolid Tumors
Click here to search clinical trials
Print PDF

Last updated 2017-10-31

For any questions please contact us.

All programs have Global Development Rights unless otherwise noted.

1 Brentuximab vedotin is co-developed by Takeda and Seattle Genetics, Inc. 2 Japan Only. 3 Japan Only. In-Licensed. 4 Takeda shares development rights with Incyte (Europe, Turkey and Israel) and Otsuka (Asia Pacific territories). 5 Ex-Us, Ex-Canada. TAK-522 (XMT-1522) is co-developed by Takeda and Mersana Therapeutics, Inc. 6 Niraparib is being developed under a licensing agreement with Tesaro, Inc. for all tumor types in Japan and all tumor types excluding prostate cancer in South Korea, Taiwan, Russia and Australia.